类风湿关节炎患者与风湿免疫科医生对改善病情抗风湿药减量的观点:一项定性研究
该定性研究通过半结构化访谈和焦点小组,探讨了28例成人类风湿关节炎(RA)患者与23名风湿免疫科医生对改善病情抗风湿药(DMARD)减量的看法。双方态度矛盾,既担忧减量后无法恢复原有疾病控制水平,也认可减少药物伤害的潜在益处。患者减量观点随时间变化,偏好受生活经历、副作用等因素影响;医生减量观点因时机和患者特征而异。研究建议将DMARD减量纳入共享决策,并确保监测和复发管理计划。
要点
- 患者和医生对DMARD减量态度矛盾,担忧无法恢复疾病控制,也认可减少药物伤害。
- 患者减量观点随时间变化,偏好受生活经历、副作用、疾病轨迹等因素影响。
- 医生减量观点因时机和患者特征而异,建议定期讨论减量并制定监测和复发管理计划。
核心结论
- 患者和医生对RA中DMARD减量的观点多样且随时间演变。
- 医生应定期与患者讨论DMARD减量作为共享决策的一部分,并确保监测和复发管理计划到位。
研究设计与样本
- 采用半结构化访谈指南,对RA患者和风湿免疫科医生进行个体访谈和焦点小组,录音并转录。
- 采用实用性主题分析识别主要主题,比较患者与医生对DMARD减量观点的异同。
- 招募28例成人RA患者(64%女性;病程1-54年)和23名风湿免疫科医生(52%女性)。
主要发现
- 双方对DMARD减量态度矛盾,从谨慎到热情不等,均担忧无法「重获」同等疾病控制水平,也认可减少药物伤害等潜在积极结果。
- 患者减量观点(是否减量及何时减量)随时间变化,常涉及非生物DMARD;偏好受生活经历、副作用、既往减量经历、疾病轨迹、缓解持续时间和当前生活角色影响。
- 医生减量观点因启动减量的时机和患者特征而异,受数据和临床经验影响。
- 患者对共享决策(SDM)和减量期间密切监测感兴趣,希望出现问题能随时联系医疗团队。
- 医生通常对减量(而非停药)持开放态度,但有时仅在患者要求时进行。
临床怎么用
- 风湿免疫科医生应定期与RA患者讨论DMARD减量,作为共享决策的一部分。
- 减量期间应确保监测和复发管理计划到位,并让患者能随时联系医疗团队。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To understand the perspectives of patients and rheumatologists for tapering DMARDs in RA. METHODS: Using semi-structured interview guides, we conducted individual interviews and focus groups with RA patients and rheumatologists, which were audiotaped and transcribed. We conducted a pragmatic thematic analysis to identify major themes, comparing and contrasting different views on DMARD tapering between patients and rheumatologists. RESULTS: We recruited 28 adult patients with RA (64% women; disease duration 1-54 y) and 23 rheumatologists (52% women). Attitudes across both groups towards tapering DMARDs were ambivalent, ranging from wary to enthusiastic. Both groups expressed concerns, particularly the inability to 'recapture' the same level of disease control, while also acknowledging potential positive outcomes such as reduced drug harms. Patient tapering perspectives (whether to and when) changed over time and commonly included non-biologic DMARDs. Patient preferences were influenced by lived experiences, side effects, previous tapering experiences, disease trajectory, remission duration and current life roles. Rheumatologists' perspectives varied on timing and patient profile to initiate tapering, and were informed by both data and clinical experience. Patients expressed interest in shared decision-making (SDM) and close monitoring during tapering, with ready access to their health-care team if problems arose. Rheumatologists were generally open to tapering (not stopping), though sometimes only when requested by their patients. CONCLUSION: The perspectives of patients and rheumatologists on tapering DMARDs in RA vary and evolve over time. Rheumatologists should periodically discuss DMARD tapering with patients as part of SDM, and ensure monitoring and flare management plans are in place.
引用
- Hazlewood GS, Loyola-Sanchez A, Bykerk V, et al. Patient and rheumatologist perspectives on tapering DMARDs in rheumatoid arthritis: a qualitative study. Rheumatology (Oxford). 2022. PMID: 33878168. doi:10.1093/rheumatology/keab330
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。